What are examples of H2‑histamine receptor antagonists?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

H2-Histamine Receptor Antagonists: Examples and Clinical Context

Primary H2-Receptor Antagonist Medications

The four main H2-histamine receptor antagonists available are cimetidine, ranitidine, famotidine, and nizatidine. 1, 2

Specific Agents with Dosing

  • Cimetidine: 30–40 mg/kg/day divided in 4 doses (pediatric); 300 mg three-four times daily (adult equivalent dosing) 1, 2

  • Ranitidine: 5–10 mg/kg/day divided in 2-3 doses (pediatric); 150 mg twice daily (adult equivalent dosing) 1, 2

  • Famotidine: 1 mg/kg/day divided in 2 doses (pediatric); 20 mg twice daily (adult equivalent dosing) 1, 2

  • Nizatidine: 10 mg/kg/day divided in 2 doses (pediatric); 150 mg twice daily (adult equivalent dosing) 1, 2

Mechanism of Action

H2-receptor antagonists decrease gastric acid secretion by competitively inhibiting the histamine-2 receptor on gastric parietal cells. 2, 3 These agents exhibit classical competitive drug-receptor interactions with rapid onset of action—gastric pH begins increasing within 30 minutes of administration, reaching peak plasma concentrations at 2.5 hours, with acid-inhibiting effects lasting approximately 6 hours. 2, 4

Relative Potency Differences

Famotidine is the most potent H2-receptor antagonist, being 20-50 times more potent than cimetidine and 6-10 times more potent than ranitidine. 4 This intrinsic potency difference translates to lower effective plasma concentrations required for famotidine compared to other agents in this class. 4, 5

Important Clinical Limitations

Tachyphylaxis Development

A critical limitation is that fairly rapid tachyphylaxis develops within 6 weeks of initiating H2-receptor antagonist treatment, substantially limiting their potential for long-term use. 2 This tolerance phenomenon reduces their clinical effectiveness over time and represents a major disadvantage compared to proton pump inhibitors.

Comparative Efficacy

H2-receptor antagonists have been shown to be less effective than proton pump inhibitors in both symptom relief and healing rates of erosive esophagitis. 2 Standard doses of H2-receptor antagonists reduce the risk of duodenal ulcers but not gastric ulcers in NSAID users, though double-dose regimens show efficacy for both. 6

Drug-Specific Adverse Effects

Cimetidine has specifically been linked to increased risk of liver disease and gynecomastia due to its antiandrogenic activity, and these associations may be generalizable to other H2-receptor antagonists. 2, 7 Cimetidine and ranitidine also inhibit the hepatic cytochrome P-450 enzyme system, leading to clinically significant drug interactions with warfarin and theophylline that require monitoring. 7 In contrast, famotidine and nizatidine do not significantly bind to cytochrome P-450 and offer a definite advantage regarding drug interaction potential. 5, 7

Current Clinical Role

H2-receptor antagonists are now primarily used for faster onset of action when needed and for control of nocturnal breakthrough reflux in patients already on proton pump inhibitor therapy. 8 Their role has diminished as first-line therapy given the superior efficacy of proton pump inhibitors and the development of tachyphylaxis with H2-receptor antagonists. 2, 8

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.